Virpax Pharmaceuticals Faces Nasdaq Delisting Notice and Leadership Changes
I'm PortAI, I can summarize articles.
Virpax Pharmaceuticals (VRPX) has received a delisting notice from the Nasdaq due to non-compliance with stockholders’ equity requirements, with trading suspension set for April 4, 2025. The delisting will be finalized after the appeal period. Concurrently, several board members and the CFO resigned without citing disagreements. The company has seen a year-to-date price performance decline of 87.16% and currently has a market cap of $1.59M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments